
RTX Corp. demonstrated its Barracuda anti-mine vehicle's successful untethered test, contributing to a robust $92 billion backlog as of Q1 2025, driven by $9 billion in Q1 bookings and strong commercial aerospace unit performance. Despite a 26.3% year-to-date stock gain, the company faces significant near-term challenges including persistent supply-chain disruptions, a premium valuation (2.25x forward P/S vs. 1.85x peer average), and declining analyst confidence in its near-term earnings outlook. The analysis concludes with a cautious stance, recommending investors avoid the stock due to these risks and a Zacks Rank #4 (Sell).
RTX Corporation exhibits a classic conflict between long-term strategic potential and significant near-term headwinds. On the positive side, the company's defense segment demonstrated technological leadership with the successful untethered test of its Barracuda anti-mine vehicle. This is supported by strong business fundamentals, including $9 billion in Q1 bookings that have built a substantial $92 billion defense backlog, providing long-term revenue visibility. Furthermore, its commercial aerospace divisions are performing well, with Collins Aerospace and Pratt & Whitney reporting year-over-year Q1 sales growth of 8% and 14%, respectively. However, these strengths are counterbalanced by considerable risks. The stock trades at a premium valuation, with a forward 12-month price-to-sales ratio of 2.25x versus a peer average of 1.85x. This rich valuation is concerning in light of persistent global supply-chain disruptions, which prompted the IATA to slash its 2025 jet delivery forecast, posing a direct threat to the Pratt & Whitney engine business. This cautious outlook is reinforced by recent downward revisions to near-term earnings estimates and a Zacks Rank of #4 (Sell), suggesting declining analyst confidence and potential for near-term underperformance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
moderately negative
Sentiment Score
-0.50
Ticker Sentiment